JPWO2019160057A1 - 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 - Google Patents
炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 Download PDFInfo
- Publication number
- JPWO2019160057A1 JPWO2019160057A1 JP2020500562A JP2020500562A JPWO2019160057A1 JP WO2019160057 A1 JPWO2019160057 A1 JP WO2019160057A1 JP 2020500562 A JP2020500562 A JP 2020500562A JP 2020500562 A JP2020500562 A JP 2020500562A JP WO2019160057 A1 JPWO2019160057 A1 JP WO2019160057A1
- Authority
- JP
- Japan
- Prior art keywords
- group
- ketamine
- bone
- mice
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 76
- 208000020084 Bone disease Diseases 0.000 title claims abstract description 73
- 239000003814 drug Substances 0.000 title claims abstract description 71
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 66
- 230000000069 prophylactic effect Effects 0.000 title claims abstract description 51
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 35
- 230000002757 inflammatory effect Effects 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 98
- 150000003839 salts Chemical class 0.000 claims abstract description 75
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 61
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 22
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 18
- 125000005843 halogen group Chemical group 0.000 claims abstract description 18
- 125000003118 aryl group Chemical group 0.000 claims abstract description 17
- 125000004431 deuterium atom Chemical group 0.000 claims abstract description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 47
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 22
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 22
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 12
- 208000001132 Osteoporosis Diseases 0.000 claims description 10
- 208000011231 Crohn disease Diseases 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 206010035664 Pneumonia Diseases 0.000 claims description 5
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-VVKOMZTBSA-N Dideuterium Chemical group [2H][2H] UFHFLCQGNIYNRP-VVKOMZTBSA-N 0.000 claims description 4
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 4
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 4
- 206010021263 IgA nephropathy Diseases 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 4
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 208000016738 bone Paget disease Diseases 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 208000007451 chronic bronchitis Diseases 0.000 claims description 4
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 4
- 201000006334 interstitial nephritis Diseases 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 230000000010 osteolytic effect Effects 0.000 claims description 4
- 208000026872 Addison Disease Diseases 0.000 claims description 3
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 201000002661 Spondylitis Diseases 0.000 claims description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000001256 tonic effect Effects 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 3
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 163
- 229960003299 ketamine Drugs 0.000 description 116
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 72
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 description 42
- 102000014128 RANK Ligand Human genes 0.000 description 42
- 108010025832 RANK Ligand Proteins 0.000 description 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 36
- 239000002504 physiological saline solution Substances 0.000 description 32
- 239000011780 sodium chloride Substances 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 229910052500 inorganic mineral Inorganic materials 0.000 description 30
- 239000011707 mineral Substances 0.000 description 30
- 230000035882 stress Effects 0.000 description 29
- 230000000694 effects Effects 0.000 description 27
- 238000011156 evaluation Methods 0.000 description 24
- 238000005259 measurement Methods 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- 230000037396 body weight Effects 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 23
- 102000008108 Osteoprotegerin Human genes 0.000 description 22
- 108010035042 Osteoprotegerin Proteins 0.000 description 22
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 21
- 230000003449 preventive effect Effects 0.000 description 19
- 230000001225 therapeutic effect Effects 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 230000037182 bone density Effects 0.000 description 17
- 229960004184 ketamine hydrochloride Drugs 0.000 description 17
- 238000001543 one-way ANOVA Methods 0.000 description 17
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 15
- 102000004264 Osteopontin Human genes 0.000 description 15
- 108010081689 Osteopontin Proteins 0.000 description 15
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 15
- 208000037976 chronic inflammation Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000001575 pathological effect Effects 0.000 description 14
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- 229960004963 mesalazine Drugs 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 108090001005 Interleukin-6 Proteins 0.000 description 11
- 238000007619 statistical method Methods 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 10
- 230000001054 cortical effect Effects 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 150000001975 deuterium Chemical group 0.000 description 10
- 229910052805 deuterium Inorganic materials 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 9
- 206010009887 colitis Diseases 0.000 description 9
- 229960002725 isoflurane Drugs 0.000 description 9
- 230000011164 ossification Effects 0.000 description 9
- 208000006386 Bone Resorption Diseases 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 206010054089 Depressive symptom Diseases 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 230000024279 bone resorption Effects 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 238000001948 isotopic labelling Methods 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 210000002997 osteoclast Anatomy 0.000 description 8
- 210000000689 upper leg Anatomy 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 238000000729 Fisher's exact test Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- -1 t. -Butyl group Chemical group 0.000 description 6
- 239000008399 tap water Substances 0.000 description 6
- 235000020679 tap water Nutrition 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 5
- 210000000963 osteoblast Anatomy 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 210000000436 anus Anatomy 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 210000004534 cecum Anatomy 0.000 description 4
- 229960001251 denosumab Drugs 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000001739 density measurement Methods 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229960001428 mercaptopurine Drugs 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000009806 oophorectomy Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000003997 social interaction Effects 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010015719 Exsanguination Diseases 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010072395 Atypical fracture Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 206010060976 Bacillus infection Diseases 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- ITBBBZIIFJJMDU-CQSZACIVSA-N CCN[C@@](CCCC1)(C1=O)c(cccc1)c1Cl Chemical compound CCN[C@@](CCCC1)(C1=O)c(cccc1)c1Cl ITBBBZIIFJJMDU-CQSZACIVSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010028140 Mucous stools Diseases 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- SQGBZKZDUMBTIJ-UHFFFAOYSA-N n-prop-2-enylcyclohexanamine Chemical compound C=CCNC1CCCCC1 SQGBZKZDUMBTIJ-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009392 systemic autoimmunity Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Abstract
Description
[1]下記式(1)で表される化合物又はその薬理学的に許容される塩を有効成分として含有する、炎症性疾患若しくは骨疾患の予防又は治療剤。
[2]下記式(2)で表される化合物又はその薬理学的に許容される塩を有効成分として含有する、[1]に記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
[3]前記炎症性疾患が、潰瘍性大腸炎、クローン病、関節リウマチ、強直性脊椎炎、インスリン依存性糖尿病、アジソン病、グッドパスチャー症候群、IgA腎症、間質性腎炎、シェーグレン症候群、自己免疫性膵炎、乾癬、アトピー性皮膚炎、肺炎、慢性気管支炎、気管支喘息、全身性紅斑性狼瘡(SLE)、強皮症又はせん妄であり、前記骨疾患が、骨粗鬆症、溶骨性骨転移又は骨パジェット病である、[1]又は[2]に記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
[4]下記式(3)で表される化合物及びその薬理学的に許容される塩を実質的に含まない、[1]〜[3]のいずれかに記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
[5]下記式(4)で表される化合物及びその薬理学的に許容される塩を実質的に含まない、[4]に記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
1実施形態において、本発明は、下記式(1)で表される化合物又はその薬理学的に許容される塩を有効成分として含有する、炎症性疾患若しくは骨疾患の予防又は治療剤を提供する。骨疾患の予防又は治療剤については後述する。実施例において後述するように、本実施形態の予防又は治療剤により、炎症性疾患を予防又は治療することができる。
1実施形態において、本発明は、上述した炎症性疾患若しくは骨疾患の予防又は治療剤と、薬理学的に許容される担体とを含有する、炎症性腸疾患若しくは骨疾患の予防又は治療用医薬組成物を提供する。骨疾患の予防又は治療用医薬組成物については後述する。
1実施形態において、本発明は、下記式(1)で表される化合物又はその薬理学的に許容される塩を有効成分として含有する、骨疾患の予防又は治療剤を提供する。実施例において後述するように、本実施形態の予防又は治療剤により、骨疾患を予防又は治療することができる。
1実施形態において、本発明は、上述した骨疾患の予防又は治療剤と、薬理学的に許容される担体とを含有する、骨疾患の予防又は治療用医薬組成物を提供する。
1実施形態において、本発明は、上記式(1)で表される化合物又はその薬理学的に許容される塩の有効量を、治療を必要とする患者に投与することを含む、炎症性疾患若しくは骨疾患の予防又は治療方法を提供する。
(炎症性疾患モデルマウス)
炎症性疾患モデルマウスにR−ケタミン及びS−ケタミンを投与し、治療効果を検討した。炎症性疾患モデルマウスとして、デキストラン硫酸塩(DSS)を投与する潰瘍性大腸炎モデルマウスを使用した。
(炎症性疾患モデルマウスの病態スコアの評価)
実験例1のスケジュールで飼育した各群のマウスにおいて、実験開始から7日目、10日目、12日目、14日目に病態スコアを算出した。病態スコアは、マウスに、生理食塩水、S−ケタミン又はR−ケタミンを投与する前に評価した。具体的には、体重減少量の評価スコア、糞の評価スコア、及び出血の評価スコアを以下の評価基準により求め、合計スコアを病態スコアとした。
生理食塩水、S−ケタミン又はR−ケタミンの投与前の体重を100%とし、各群のマウスの体重減少量を下記表1に記載の評価基準で評価した。
下記表2に記載の評価基準により、各群のマウスの糞を評価した。
下記表3に記載の評価基準により、各群のマウスの出血を評価した。
図2は、各群のマウスの病態スコアを示すグラフである。図2中、「対照」は、対照群のマウスの結果を示し、「DSS+生理食塩水」はDSS及び生理食塩水を投与した群のマウスの結果を示し、「DSS+S−ケタミン」はDSS及びS−ケタミンを投与した群のマウスの結果を示し、「DSS+R−ケタミン」はDSS及びR−ケタミンを投与した群のマウスの結果を示す。
(炎症性疾患モデルマウスの大腸炎症スコアの評価)
実験例1において、実験開始から15日目に安楽死させた各群のマウスについて、大腸炎症スコアを評価した。
(血液中の炎症性サイトカインの評価)
実験例1において、実験開始から15日目に各群のマウスから採取した血漿中の炎症性サイトカインを定量した。炎症性サイトカインとして、インターロイキン(IL)−6を定量した。IL−6の定量は、市販のキットを用いたELISA法により行った。
(社会的敗北ストレスモデルマウスの作製)
まず、既知の方法により、「社会的敗北ストレス」と呼ばれるストレスを与えたモデルマウスを作製した。具体的には、C57/B6雄性マウス(7週齢、日本SLC株式会社)及びICR雄性マウス(9週齢以上、日本SLC株式会社)を1匹ずつ10日間同居させた。各マウスには、水及び飼料を自由に摂取させた。ICRマウスはC57/B6マウスよりも体が大きく攻撃的であるため、これらのマウスを同居させるとC57/B6がストレスを受けることになる。
(社会的敗北ストレスモデルマウスへのR−ケタミン投与の影響の検討)
実験例5で作製した、うつ症状を呈したマウス(以下、「社会的敗北ストレスマウス」という場合がある。)に、R−ケタミン及びS−ケタミンを投与し、その影響を検討した。R−ケタミンとして、R−ケタミン塩酸塩を使用した。また、S−ケタミンとして、S−ケタミン塩酸塩を使用した。R−ケタミン塩酸塩及びS−ケタミン塩酸塩は、実験例1と同様にして調製した。
(炎症性疾患モデルマウス)
炎症性疾患モデルマウスに、生理食塩水、潰瘍性大腸炎の標準薬である5−アミノサリチル酸(5−ASA)又はR−ケタミンをそれぞれ投与し、治療効果を検討した。炎症性疾患モデルマウスとして、実験例1と同様のデキストラン硫酸塩(DSS)を投与する潰瘍性大腸炎モデルマウスを使用した。R−ケタミンとしては、実験例1と同様にして調製したR−ケタミン塩酸塩を使用した。
(炎症性疾患モデルマウスの病態スコアの評価)
実験例7のスケジュールで飼育した各群のマウスにおいて、実験開始から7日目、10日目、12日目、14日目に病態スコアを算出した。病態スコアは、マウスに、生理食塩水、5−ASA又はR−ケタミンを投与する前に評価した。具体的には、体重減少量の評価スコア、糞の評価スコア、及び出血の評価スコアを実験例2と同様の評価基準により求め、合計スコアを病態スコアとした。
(炎症性疾患モデルマウスの大腸炎症スコアの評価)
実験例7において、実験開始から15日目に安楽死させた各群のマウスについて、大腸炎症スコアを評価した。
(血液中の炎症性サイトカインの評価)
実験例7において、実験開始から15日目に各群のマウスから採取した血漿中の炎症性サイトカインを定量した。炎症性サイトカインとして、IL−6を定量した。IL−6の定量は、市販のキットを用いたELISA法により行った。
(社会的敗北ストレスモデルマウスへのR−ケタミン及びその代謝物の投与の影響の検討)
実験例5と同様にして作製した、うつ症状を呈したマウス(以下、「社会的敗北ストレスマウス」という場合がある。)に、R−ケタミン及びR−ケタミンの代謝物を投与し、その影響を検討した。R−ケタミンとして、実験例1と同様にして調製したR−ケタミン塩酸塩を使用した。また、R−ケタミンの代謝物として、R−ケタミンの最終代謝物である2R,6R−ヒドロキシノルケタミンの塩酸塩(2R,6R−HNK塩酸塩)を使用した。R−ケタミン塩酸塩及び2R,6R−HNK塩酸塩は、生理食塩水に溶解して使用した。
(骨粗鬆症モデル動物へのR−ケタミンの投与の検討1)
多くの研究から、骨粗鬆症患者の血液では、RANKLの濃度が高いことが報告されており、ヒト型抗RANKLモノクローナル抗体製剤(デノスマブ)が治療薬として使用されている。本実験例では、骨粗鬆症のモデル動物として、sRANKLを投与したマウスを使用し、R−ケタミンの効果を検討した。
(骨粗鬆症モデル動物へのR−ケタミンの投与の検討2)
骨粗鬆症のモデル動物として、卵巣摘出を施行したマウスを使用し、R−ケタミンの効果を検討した。
Claims (6)
- 前記炎症性疾患が、潰瘍性大腸炎、クローン病、関節リウマチ、強直性脊椎炎、インスリン依存性糖尿病、アジソン病、グッドパスチャー症候群、IgA腎症、間質性腎炎、シェーグレン症候群、自己免疫性膵炎、乾癬、アトピー性皮膚炎、肺炎、慢性気管支炎、気管支喘息、全身性紅斑性狼瘡(SLE)、強皮症又はせん妄であり、前記骨疾患が、骨粗鬆症、溶骨性骨転移又は骨パジェット病である、請求項1又は2に記載の炎症性疾患若しくは骨疾患の予防又は治療剤。
- 請求項1〜5のいずれか一項に記載の炎症性疾患若しくは骨疾患の予防又は治療剤と、薬理学的に許容される担体とを含有する、炎症性疾患若しくは骨疾患の予防又は治療用医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018025170 | 2018-02-15 | ||
JP2018025170 | 2018-02-15 | ||
JP2018121858 | 2018-06-27 | ||
JP2018121858 | 2018-06-27 | ||
PCT/JP2019/005415 WO2019160057A1 (ja) | 2018-02-15 | 2019-02-14 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2019160057A1 true JPWO2019160057A1 (ja) | 2021-02-04 |
JPWO2019160057A5 JPWO2019160057A5 (ja) | 2022-02-24 |
Family
ID=67618723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020500562A Pending JPWO2019160057A1 (ja) | 2018-02-15 | 2019-02-14 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210000762A1 (ja) |
EP (1) | EP3753557A4 (ja) |
JP (1) | JPWO2019160057A1 (ja) |
CN (1) | CN111936127A (ja) |
BR (1) | BR112020016500A2 (ja) |
TW (1) | TW201936567A (ja) |
WO (1) | WO2019160057A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS62516B1 (sr) | 2013-09-13 | 2021-11-30 | Univ Chiba Nat Univ Corp | Primena r-ketamina i njegove soli kao farmaceutskih proizvoda |
EP3813808A4 (en) | 2018-05-04 | 2022-01-26 | Perception Neuroscience, Inc. | DRUG TREATMENT METHODS |
CA3165903A1 (en) | 2019-12-26 | 2021-07-01 | Gilgamesh Pharmaceuticals, Inc. | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders |
CN115135320B (zh) | 2020-02-18 | 2023-08-29 | 吉尔伽美什制药公司 | 用于治疗情绪障碍的特定色胺 |
CA3234818A1 (en) | 2021-10-12 | 2023-04-20 | Perception Neuroscience, Inc. | R-ketamine salts and methods of use thereof |
WO2023178039A1 (en) | 2022-03-14 | 2023-09-21 | Perception Neuroscience, Inc. | Pharmaceutical formulations of r-ketamine |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010525081A (ja) * | 2007-04-26 | 2010-07-22 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 重水素標識ケタミン |
JP2015078181A (ja) * | 2013-09-13 | 2015-04-23 | 国立大学法人 千葉大学 | R−ケタミンおよびその塩の医薬品としての応用 |
WO2017180589A1 (en) * | 2016-04-11 | 2017-10-19 | Auspex Pharmaceuticals, Inc. | Deuterated ketamine derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
AU3868001A (en) | 2000-02-23 | 2001-09-03 | Amgen Inc | Antagonistic selective binding agents of osteoprotegerin binding protein |
JP6327591B2 (ja) | 2016-08-12 | 2018-05-23 | マツダ株式会社 | ディーゼルエンジンの制御方法及び制御システム |
JP6926383B2 (ja) | 2017-01-31 | 2021-08-25 | 日本製紙クレシア株式会社 | 吸収性補助パッド及びその使用方法 |
-
2019
- 2019-02-14 BR BR112020016500-0A patent/BR112020016500A2/pt unknown
- 2019-02-14 JP JP2020500562A patent/JPWO2019160057A1/ja active Pending
- 2019-02-14 EP EP19754880.3A patent/EP3753557A4/en active Pending
- 2019-02-14 US US16/969,713 patent/US20210000762A1/en active Pending
- 2019-02-14 WO PCT/JP2019/005415 patent/WO2019160057A1/ja unknown
- 2019-02-14 CN CN201980013557.XA patent/CN111936127A/zh active Pending
- 2019-02-15 TW TW108105200A patent/TW201936567A/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010525081A (ja) * | 2007-04-26 | 2010-07-22 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 重水素標識ケタミン |
JP2015078181A (ja) * | 2013-09-13 | 2015-04-23 | 国立大学法人 千葉大学 | R−ケタミンおよびその塩の医薬品としての応用 |
WO2017180589A1 (en) * | 2016-04-11 | 2017-10-19 | Auspex Pharmaceuticals, Inc. | Deuterated ketamine derivatives |
Non-Patent Citations (4)
Title |
---|
ASHRY EE ET AL.: "Protective Effect of Ketamine against Acetic Acid-Induced Ulcerative Colitis in Rats", PHARMACOLOGY & PHARMACY, vol. 7, JPN6019013389, 2016, pages 9 - 18, XP055634621, ISSN: 0004982945, DOI: 10.4236/pp.2016.71002 * |
CANADIAN JOURNAL OF ANESTHESIA, vol. 48, JPN6023004341, 2001, pages 819 - 823, ISSN: 0004982944 * |
KADRIU B ET AL.: "Acute Ketamine Administration Corrects Abnormal Inflammatory Bone Markers in Major Depressive Disord", MOLECULAR PSYCHIATRY, vol. 23, JPN6019013390, 30 May 2017 (2017-05-30), pages 1626 - 1631, XP036725721, ISSN: 0004982946, DOI: 10.1038/mp.2017.109 * |
ZHANG JC ET AL.: "R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine", PHARMACOLOGY, BIOCHEMISTRY AND BEHAVIOR, vol. 116, JPN6019013391, 2014, pages 137 - 141, XP055158236, ISSN: 0004982947, DOI: 10.1016/j.pbb.2013.11.033 * |
Also Published As
Publication number | Publication date |
---|---|
US20210000762A1 (en) | 2021-01-07 |
CN111936127A (zh) | 2020-11-13 |
BR112020016500A2 (pt) | 2020-12-15 |
WO2019160057A1 (ja) | 2019-08-22 |
TW201936567A (zh) | 2019-09-16 |
EP3753557A4 (en) | 2021-12-01 |
EP3753557A1 (en) | 2020-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2019160057A1 (ja) | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 | |
JP6931019B2 (ja) | 多発性硬化症を処置するためのs1p受容体モジュレーター | |
JP6754071B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
KR101996245B1 (ko) | 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물 | |
US11135212B2 (en) | Method for treating osteoporosis, osteopenia or low bone mineral density | |
JP2021507889A (ja) | ピラゾロピペリジン誘導体の新規な使用 | |
CN107405347B (zh) | 用于治疗处理或美容处理过量体脂肪的nk-3受体拮抗剂 | |
KR102277739B1 (ko) | 벤즈히드릴 티오 아세트아미드 화합물을 유효성분으로 포함하는 섬유화 질환의 치료용 조성물 | |
US20160287535A1 (en) | Uses and Methods for the Treatment of Liver Diseases or Conditions | |
US20210137905A1 (en) | 1-piperidinepropionic acid for treating a fibrosing disease | |
JP7290223B2 (ja) | IL-1β阻害薬 | |
KR102512518B1 (ko) | 페마피브레이트를 함유하는 의약 | |
WO2020067333A1 (ja) | 線維症治療用医薬組成物 | |
JP7233087B2 (ja) | 抗動脈硬化剤 | |
WO2023190976A1 (ja) | 呼吸器疾患治療剤 | |
KR102390194B1 (ko) | 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물 | |
KR20190013847A (ko) | 불안 장애를 치료하기 위한 (2S)-1-[4-(3,4-디클로로페닐)피페리딘-1-일]-3-[2-(5-메틸-1,3,4-옥사디아졸-2-일)벤조[b]푸란-4-일옥시]프로판-2-올 또는 그의 대사산물 | |
WO2021010348A1 (ja) | うつ病またはうつ症状の予防または治療剤としてのトランスフォーミング増殖因子β1 | |
WO2022097287A1 (ja) | Eomes陽性CD4陽性T細胞の増加に起因する進行型疾患治療剤 | |
RU2569732C9 (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза | |
EP3782648A1 (en) | Preventative and therapeutic agents for sarcopenia | |
JP2021084889A (ja) | 低分子化合物クプリゾンおよびその誘導体による体脂肪量減少効果 | |
JP2020533353A (ja) | アルコール性肝炎の治療のためのil−1b結合抗体の使用 | |
JP2005053890A (ja) | アディポネクチン濃度低下及び/又はc反応性蛋白濃度上昇及び/又はil−18濃度上昇に起因する疾患の予防及び/又は治療剤。 | |
CA2750265A1 (en) | Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220214 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230406 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230627 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231026 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240116 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240308 |